Hot Flashes clinical trials

Explore recruiting hot flashes clinical trials.

Recruiting hot flashes studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hot Flashes trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized intrapatient cross-over study to assess the efficacy of oxybutynin versus venlafaxine in REDucing hot FLASHes in women using endocrine therapy after breast cancer: the RED FLASH study.

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis: Randomised Prospective Study.

France

Phase III and phase IV (Integrated) EU CTIS Study details

A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women with Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy

Hungary, Denmark, Italy, Czechia, Germany, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms caused by adjuvant endocrine therapy, over 52 weeks and optionally for additional up to 3.5 years in women with, or at high risk for developing hormone-receptor positive breast cancer

Hungary, Finland, Poland, France, Spain, Portugal +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

(22424) Exploratory, randomized, non-blinded, crossover study to investigate the relative bioavailability of different elinzanetant soft gel capsules in healthy participants

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A study to learn how much elinzanetant gets into the blood, how safe it is and how it affects the body after taking single and multiple amounts in healthy subjects

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Hot Flashes trials by city

Hot Flashes in Toronto Hot Flashes in Vancouver Hot Flashes in Montreal Hot Flashes in Calgary Hot Flashes in Edmonton Hot Flashes in Ottawa Hot Flashes in Winnipeg Hot Flashes in Quebec City Hot Flashes in Hamilton Hot Flashes in Kitchener Hot Flashes in London Hot Flashes in Halifax Hot Flashes in New York Hot Flashes in Los Angeles Hot Flashes in Chicago Hot Flashes in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease